Abstract. Silymarin has been used in the treatment of a number of liver diseases for a long time, but its efficacy in preventing triptolide induced acute hepatotoxicity has not been reported previously. The present study aimed to assess the protective effect of silymarin against triptolide (TP)-induced hepatotoxicity in rats. Rats were orally administrated with silymarin (50, 100 and 200 mg/kg) for 7 days and received intraperitoneal TP (2 mg/kg) on the day 8. Hepatic injuries were comprehensively evaluated in terms of serum parameters, morphological changes, oxidative damage, inflammation and apoptosis. The results demonstrated that TP-induced increases in serum parameters, including alanine transaminase, aspartate aminotransferase, alkaline phosphatase, total cholesterol and γ-glutamyl transpeptidase, which were determined using a biochemical analyzer, and histopathological alterations and hepatocyte apoptosis as determined by hematoxylin and eosin and TUNEL staining, respectively, were prevented by silymarin pretreatment in a dose-dependent manner. TP-induced depletions in the activity of the antioxidant enzymes superoxide dismutase, glutathione peroxidase, glutathione S-transferase and catalase, and glutathione levels, were also significantly reversed by silymarin, as determined using specific kits. Additionally, silymarin dose-dependently exhibited inhibitory effects on malonaldehyde content in the liver. The production of proinflammatory cytokines was investigated using ELISA kits, and the results demonstrated that silymarin dose-dependently inhibited the production of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10 and IL-1β in the liver. To determine the mechanism of silymarin, western blot analysis was performed to investigate the protein expression of phosphorylated (p)-p38 and p-c-Jun N-terminal kinase (JNK) of the TNF-α induced inflammatory response and apoptotic pathways. Silymarin significantly blocked p38 and JNK phosphorylation and activation. Additionally, the expression of the proapoptotic proteins cytochrome c, cleaved caspase-3 and Bcl-2-associated X was also reduced following treatment with silymarin, as determined by ELISA, western blotting and immunohistochemistry, respectively. In conclusion, silymarin was demonstrated to dose-dependently protect rat liver from TP-induced acute hepatotoxicity, with the high dose (200 mg/kg) achieving a superior effect. This protective effect may be associated with the improvement of antioxidant and anti-inflammatory status, as well as the prevention of hepatocyte apoptosis. Therefore, silymarin may have the potential to be applied clinically to prevent TP-induced acute hepatotoxicity.

Introduction

Triptolide (TP; C 20 H 24 O 6 ; Fig. 1A), a diterpene triepoxide, is derived from the traditional Chinese medicinal herb
**Materials and methods**

**Materials.** TP (purity >98% by high-performance liquid chromatography analysis) was supplied by the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Silymarin was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and consisted primarily of silybinin (>30%), iso-silybinin, silicristin and silidianin. TP was dissolved in 0.05% dimethyl sulfoxide saline. Silymarin was suspended in 0.5% sodium carboxymethyl cellulose (CMC-Na) distilled water solution. Other chemicals and reagents used were of analytical grade.

**Animals.** A total of 60 male Wistar rats (weight, 220±20 g; 6-8 weeks) were obtained from the Experimental Animal Center of Guangzhou University of Chinese Medicine (Guangzhou, China). All the experiments were performed in a specific-pathogen free laboratory at a controlled temperature of 25±2°C and relative humidity of 35-75% on a 12 h light/dark cycle. Animals had free access to rat chow and tap water. All experimental protocols were in compliance with the guidelines of the Committee for Animal Care and Use of Guangzhou University of Chinese Medicine, and were approved by the ethical committee of Guangzhou University of Chinese Medicine.

**Animal grouping.** Rats were randomly divided (n=12/group) into five experimental groups. Normal control (NC) and triptolide (TP) groups received oral administration of normal saline (1 ml/100 g), whereas silymarin-treated groups were orally administrated with silymarin (50, 100 and 200 mg/kg) dissolved in 0.5% CMC-Na distilled water. The doses of silymarin employed in the present study were based on our prior trial and previous study (21). Following treatment with normal saline or silymarin for 7 consecutive days, all groups, excluding the NC group, were given TP (2 mg/kg) by intraperitoneal injection to establish the liver injury animal model. At the end of the experimental period (day 8), all rats were fasted for 12 h. On the following day, the animals were anesthetized with an intraperitoneal injection of 10% chloral hydrate. Blood samples were collected from the abdominal aorta, and rats were subsequently sacrificed by spinal dislocation and liver tissue was collected from the left lobe.

**Blood biochemical studies.** Blood samples were placed at room temperature for 1 h. Following centrifugation at 1,000 x g for 10 min at room temperature, the serum was separated for biochemical estimations. The serum levels of ALT, AST, alkaline phosphatase (ALP), total cholesterol (TC) and γ-glutamyl transferase (GGT) were measured using a Hitachi-7180 type biochemical analyzer following the standard methods.

**Preparation of liver homogenate and sections.** The liver tissues were chopped into 1 cm² sections and divided into two groups. One was prepared to make 1:9 (w/v) homogenates with cold saline or phosphate buffer saline (PBS) using a tissue homogenizer (IKA T 18 Basic). The homogenate was centrifuged at 1,000 x g for 10 min at 4°C to obtain the supernatant for subsequent determinations. The other group of
liver tissues were fixed in 10% formalin at room temperature for at least 24 h for further observation of tissue sections.

Measurement of antioxidant enzymatic activities and lipid peroxidation. The supernatant of normal saline homogenates was used to measure the activities of the important antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione S-transferase (GST) and catalase (CAT), as well as glutathione (GSH) and malonaldehyde (MDA) levels in the liver, according to the manufacturer's instructions [total SOD assay kit (hydroxylamine method), GSH-PX assay kit (colorimetric method), GST assay kit (colorimetric method), GSH assay kit (colorimetric method), CAT assay kit (ultraviolet) and MDA assay kit (TBA method); Nanjing Jiancheng Bioengineering Institute, Nanjing, China].

Hepatic cytokine and cytochrome assays. The levels of inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10, IL-1β, and cytochrome c (Cyt C) levels were measured in supernatants using specific ELISA kits [E-30644 (IL-6), E-30418 (IL-1β), E-30633 (TNF-α), E-30649 (IL-10) and E-30273 (Cyt C); Beijing Chenglin Biotechnology, Beijing, China] according to the manufacturer's instructions.

Histopathological examination. After being fixed in 10% formalin for 24 h, the liver tissue was dehydrated in graded ethanol (50-100%), cleared in xylene and embedded in paraffin wax. The paraffin sections (5 µm thickness) were examined for pathological changes in the liver tissue using a light microscope (BK-DM320; Chongqing Optec Instrument Co., Ltd., Chongqing, China) and photographed at x200 magnification following hematoxylin and eosin (H&E) staining for 5-10 min at room temperature.

Detection of apoptosis. A terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL) apoptosis detection kit (Nanjing Lufei Biotechnology Co., Ltd., Nanjing, China) was used to assess the apoptosis rate of liver cells. Paraffin sections (5 µm) were incubated with the TUNEL reaction mixture at 37˚C for 60 min, then incubated with converter-POD in a humidified chamber for 30 min at 37˚C followed by incubation with DAB substrate (5 µl 20X DAB, 1 µl 30% H2O2, and 94 µl 1 PBS) for 10 min at 20˚C. The sections were washed and mounted in PBS. A total of 15 fields (x200 magnification) for each section were randomly selected to quantify the positive cells and define the apoptosis indexes using ImageJ software (version 1.50; National Institutes of Health, Bethesda, MD, USA).

Immunohistochemical staining and quantitative analysis. Immunohistochemical analyses were performed to determine the expression of Bcl-2-associated X (Bax) and Bcl-2 in the liver. Paraffin sections (5 µm thick) of the liver tissue were initially processed by dehydration. Following retrieval by citrate buffer (pH=6) microwave antigen retrieval for 15 min, 3% H2O2 was added to inactivate endogenous enzymes for another 15 min. Then, 5% normal goat serum (ab7481; Abcam, Cambridge, UK) diluted with PBS was used to block non-specific binding for 10 min at room temperature. Subsequently, sections were washed with 0.01 mol/l PBS following incubation of sections with 50 µl rabbit monoclonal antibodies for Bcl-2 (1:100, ab59348) and Bax (1:100; ab53154) (both from Abcam) at 4˚C overnight. The secondary antibody was goat anti-rabbit IgG H&L (HRP) (1:100, ab6721; Abcam) for 30 min at 37˚C. The slides were counterstained with hematoxylin (Modified Mayer’s, ab220365; Abcam) for 2-3 min at room temperature. Finally, the sections were reacted with a staining solution containing 0.03% 3,3′-diaminobenzidine (Nanjing Lufei Biotechnology Co., Ltd.,) for 5-10 min at room temperature. The sections were observed with an Olympus IX71 fluorescence microscope (Olympus Corporation, Tokyo, Japan) at x200 magnification. A total of 15 fields in each section were randomly selected to quantitatively cells by ImageJ software (version 1.50; National Institutes of Health).

Western blotting for cleaved caspase-3 (c-caspase-3), phosphorylated (p)-p38 and p-c-Jun N-terminal kinase (JNK) protein expression. Western blot analysis was performed to examine the expression of c-caspase-3, which stimulates cell apoptosis, and TNF-α induced phosphorylation of p38 and JNK in the inflammatory pathway. Liver tissue was homogenized with proteinase inhibitor on ice to obtain total protein extract according to the protocol of the T-PER Tissue Protein Extraction reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Protein concentration was determined following the protocol of a BCA protein assay kit (G2026; Wuhan Goodbio Technology Co., Ltd., Wuhan, China). Extracts containing equal amounts of protein (50 µg) were separated by 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes, which were blocked at room temperature for 1 h in 0.5% TBST (50 mmol/l Tris-HCl, pH 7.6; 150 mmol/l NaCl; 0.1% Tween-20) containing 5% non-fat milk and subsequently incubated with primary rabbit anti-rat polyclonal antibodies against c-caspase-3 (1:1000, 9661; Cell Signaling Technology, Inc., Danvers, MA, USA) and β-actin (1:1000, GB13001-1; Wuhan Goodbio Technology Co., Ltd.), and rabbit anti-rat monoclonal antibodies against p-p38 (1:1000, 4511) and p-JNK (1:1000, 4671) (both from Cell Signaling Technology, Inc.) overnight at 4˚C. β-actin was used as an internal control. All primary antibodies were purchased from Cell Signaling.
Technology, Inc. Subsequently, the membranes were washed with TBST for 15 min and incubated with secondary antibodies (anti-rabbit IgG, HRP-linked antibody, 1:3,000; Cell Signaling Technology, Inc.) labeled with horseradish peroxidase for 30 min at room temperature, followed by washing with TBST for 15 min. The membranes were then developed using an electrochemiluminescence kit (G2014; Wuhan Goodbio Technology Co., Ltd.) and the densities of the immunoreactive bands were analyzed using ImageJ software (version 1.50; National Institutes of Health).

**Statistical analysis.** Data are presented as the mean ± standard deviation. One-way analysis of variance followed by Fisher’s least significant difference tests was performed to statistically analyze the data. SPSS software (version 16; SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. P<0.05 was considered to indicate a statistically significant difference.

**Results**

*Silymarin reduces the serum levels of biochemical parameters.***

The levels of ALT, AST, ALP, TC and GGT were estimated in serum samples as sensitive biomarkers of liver function. These enzymes (ALT, AST, ALP and GGT) were enzymes derived from the injured liver tissue cells. As presented in Table I, the levels of these serum biochemical parameters in the TP group were significantly higher compared with the NC group (P<0.01), which was indicative of liver dysfunction. However,
the levels of these indicators in the three silymarin-pretreated groups markedly reduced to normal levels in a dose-dependent manner, indicating that silymarin may effectively ameliorate TP-induced liver injury.

Silymarin alleviates alteration of histological structure. Hepatic histological changes directly depict the degree of liver injury. To morphologically characterize the potential pathological alternations in hepatocytes, routine H&E staining was performed. As demonstrated in Fig. 2A, a clear and regular lobular structure was observed, where hepatic cords remained legible and radiated from the central vein in the NC group. Compared with the NC group, hepatic parenchymal necrosis and inflammatory cell infiltration was apparent, and disordered hepatic cords accompanied by extensive vacuola- tion congestion was also observed in the TP group (Fig. 2B), which was consistent with the assay results for biochemical parameters in the serum, indicating the successful establishment of the hepatic injury model. Furthermore, hepatocytes were markedly swollen, with condensed karyons and loosened cytoplasts. However, silymarin pretreatment of three tested doses appeared to alleviate TP-induced liver injury in a dose-dependent manner, as evidenced by reduced inflammation infiltration, intact tissue structure, and reduced necrotic and apoptotic mass (Fig. 2C-E), compared with the TP group. Cell apoptosis and inflammatory infiltration was particularly limited when subjected to silymarin pretreatment at the doses of 100 and 200 mg/kg.

Silymarin upregulates antioxidant enzymatic activities. As demonstrated in Fig. 3A-E, TP administration markedly reduced the activities of the antioxidant enzymes SOD, GSH-Px, CAT and GST and GSH levels by 40.61, 28.18, 45.10, 35.97 and 79.81%, respectively, compared with the NC group (P<0.05). However, pretreatment with silymarin, particularly at middle and high doses, significantly upregulated the activities compared with the TP group (P<0.05). Furthermore, silymarin significantly elevated the CAT and GST activities to levels that surpassed those in the NC group (Fig. 3A and E). Therefore, silymarin exhibited excellent effects in mitigating TP-induced systemic antioxidant enzyme exhaustion.

Silymarin suppresses TP-induced lipid peroxidation. The hepatic MDA level was determined to evaluate the degree of lipid peroxidation (Fig. 3F). MDA content increased significantly in the liver of the rats in the TP group compared with...
WANG et al. Silymarin protects against triptolide-induced liver injury in rats

794

the NC group (P<0.01). However, silymarin significantly suppressed this excessive accumulation of MDA compared with the TP group (P<0.01), and no significant difference was observed between the NC and high-dose silymarin group. Therefore, silymarin markedly suppressed TP-induced lipid peroxidation, which was consistent with the improvement in antioxidant enzymatic activities.

Silymarin decreases the production of inflammatory cytokines. An excessive inflammatory response is associated with oxidative stress (22). In the present study, the levels of important inflammatory cytokines, TNF-α, IL-1β, IL-6 and IL-10, in the liver were determined. The levels of these inflammatory mediators were significantly higher in the TP group compared with the NC group (Fig. 4), indicating that TP induced severe inflammatory response in the liver. Promisingly, pretreatment with silymarin significantly inhibited the production of these proinflammatory factors in a dose-dependent manner compared with the TP group (P<0.01). These results indicate that silymarin may attenuate TP-induced liver injury by suppressing the inflammatory response.

Silymarin inhibits transduction of the inflammatory pathway and reduces c-caspase-3 protein expression. To illustrate the underlying mechanism of silymarin inhibiting inflammatory responses, the protein expression of key downstream proteins in the TNF-α pathway, and the apoptosis-associated protein c-caspase-3, was measured (Fig. 5A). Expression levels of p-p38 in the TP group were 3.5 times higher compared with the NC group (P<0.01). However, the overexpression of p-p38 induced by TP was reduced by 20.04, 33.11 and 48.44% in silymarin treated groups in a dose-dependent manner (Fig. 5B). A similar inhibitory effect of silymarin was also observed in the expression of p-JNK. The level of p-JNK in TP group was three times higher compared with the NC group (P<0.01). In silymarin pretreated groups, the level of p-JNK decreased by 8.82, 14.93 and 61.46% in low, middle and high-dose groups, respectively, compared with the TP group (Fig. 5C). Therefore, the results indicated that silymarin, particularly at 100 and 200 mg/kg, significantly inhibited the phosphorylation of inflammatory mediators that are induced by TNF-α. In addition, the protein expression of c-caspase-3, a protein associated with apoptosis, was also determined by western blot analysis. Following TP injection, the level of c-caspase-3 in the TP group was 2.24 times higher compared with the NC group (P<0.01). In silymarin-treated groups, the expression level of c-caspase-3 was significantly decreased by 10.55, 22.93 and 29.73% in silymarin low, middle and high-dose groups, respectively, compared with the TP group (P<0.01; Fig. 5D). These results indicate that silymarin may also exert antiapoptotic effects in the liver of TP-treated rats.

Silymarin inhibits hepatocyte apoptosis. The apoptosis rates of different treatment groups were detected using TUNEL staining and quantified by ImageJ software, and representative photographs were taken under a light microscope. As demonstrated in Fig. 6, TP administration resulted in numerous TUNEL-positive hepatocytes and a significantly higher apoptotic index compared with the NC group (Table II), indicating the induction of severe hepatic apoptosis within 24 h of treatment with TP. However, fewer TUNEL-positive hepatocytes and significantly decreased apoptotic indexes (P<0.01) were observed in livers pretreated with silymarin compared with the TP group, indicating that silymarin pretreatment may protect the liver against TP-induced hepatic injury. Notably,
high-dose silymarin pretreatment exhibited a superior effect in inhibiting the cell apoptosis. These results indicated that silymarin may effectively ameliorate the hepatocyte apoptosis induced by TP.

Effects of silymarin on the expression of apoptosis-associated proteins. Representative photographs of different treatment groups were taken under a light microscope. The positive rates were calculated by ImageJ software based on 15 images of each group. No significant alterations in the expression of the antiapoptotic protein Bcl-2 were observed between NC, TP and silymarin treatment groups (Fig. 7 and Table II). By contrast, the expression of the proapoptotic protein Bax was significantly higher in the TP group compared with the NC group (P<0.01; Fig. 8 and Table II). However, silymarin significantly inhibited the expression of Bax and, therefore, the ratio of Bax/Bcl-2 was also lowered, compared with the TP group in a dose-dependent manner (P<0.01; Fig. 8 and Table II). As described above for western blot results, the changes in the levels of c-caspase-3 exhibited a similar pattern to Bax expression (Fig. 5). Furthermore, Cyto C levels in supernatants were measured by ELISA, and levels were significantly increased in the TP group compared with the NC group (P<0.01; Table II). However, silymarin pretreatment was observed to progressively reduce hepatic Cyto C levels in a dose-dependent manner compared with the TP group.

Table II. Positive rates for TUNEL analysis, Bcl-2 and Bax immunohistochemistry, Bax/Bcl-2 expression ratio and Cyto C content in the liver tissue of different treatment groups.

| Group   | Cyt C (nmol/l) | TUNEL (%) | Bcl-2 (%) | Bax (%) | Bax/Bcl-2 ratio |
|---------|----------------|-----------|-----------|---------|-----------------|
| NC      | 105.8±9.2      | 8.5±0.3   | 28.5±1.1  | 7.2±0.7 | 0.27±0.1        |
| TP      | 290.6±10.3a    | 30.6±1.0a | 29.6±0.6  | 34.9±1.1a| 1.19±0.2a       |
| SLT     | 235.0±10.6b    | 15.9±0.7b | 28.2±0.9  | 19.0±0.9b| 0.68±0.1b       |
| SMT     | 191.4±9.8b     | 12.9±0.8b | 28.4±0.8  | 10.0±0.7b| 0.37±0.1b       |
| SHT     | 156.9±6.5b     | 10.6±0.4b | 29.0±0.5  | 3.7±0.5b | 0.14±0.1b       |

Doses of 50, 100 and 200 mg/kg silymarin were employed in SLT, SMT and SHT groups, respectively. Data are presented as the mean ± standard deviation, n=12. *P<0.01 vs. NC group; **P<0.01 vs. TP group. Cyt C, cytochrome c; TUNEL, terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling; Bax, Bcl-2-associated X; NC, normal control; TP, triptolide; SLT, low-dose silymarin treatment; SMT, middle-dose silymarin treatment; SHT, high-dose silymarin treatment.
These results are consistent with those for TUNEL staining and c-caspase-3 protein expression, indicating that an antiapoptotic effect may contribute to the protective action of silymarin in the liver of TP-treated rats.

**Discussion**

The liver has a vital role in drug metabolism and is a target organ that is affected by toxicants (23). TWHF, TP and their
preparations have been widely used for autoimmune and inflammatory diseases with pronounced efficacy. Unfortunately, their application has been increasingly restricted due to their potential adverse effects and acute toxicity, particularly hepatic toxicity. To date, various studies have been performed with the aim of identifying strategies to reduce the side effects of these agents (24-26). However, counteractive therapeutic approaches against TP-induced hepatotoxicity are yet to be established. Therefore, the development of effective strategies to counteract TP toxicity is urgently required. Certain herbal drugs, including *Glycyrrhiza glabra* L. (27), *Curcuma longa* L. (28) and *Salvia miltiorrhiza* Bunge (29), have been demonstrated to improve the regeneration of liver cells, which accelerates the healing process, and are therefore commonly employed in the management of various liver disorders. It is thought that *Silybum marianum* has been applied extensively for more than 2,000 years as a natural hepatoprotective agent for the treatment of hepatic diseases, including hepatitis and cirrhosis, and to protect the liver from toxic substances (10,30). At present, silymarin, the major active component of *Silybum marianum*, is a major ingredient in a variety of pharmaceutical preparations, Chinese and Western, that are used to treat liver dysfunction (12). The present study provides additional evidence to support our hypothesis that silymarin pretreatment may prevent TP-induced hepatotoxicity, which may occur by ameliorating oxidative stress, elevating antioxidant enzymes activities, and inhibiting lipid peroxidation, the inflammatory response and apoptosis.

Alterations in serum biochemical parameters and histological structure are directly indicative of pathological status in liver. Excessive levels of serum AST, ALT, ALP, TC and GGT, which are released from damaged hepatocytes into bloodstream, are associated with severe liver dysfunction in clinical practice (31). In the present study, a single administration of TP led to severe liver injury in rats in the TP group, as evidenced by significant increases in serum AST, ALT, ALP, TC and GGT compared with the NC group, which was consistent with previous studies (32,33). The results of the present study also demonstrated that silymarin pretreatment significantly reduced TP-induced increases in the levels of these parameters, indicating improvements in hepatic function. Increases in these serum biomarkers were further validated by histopathological examination. TP caused obvious damage to the hepatic architecture and led to serious pathological abnormalities, including vacuole formation, inflammatory infiltration and focal necrosis. However, pretreatment with silymarin markedly reduced the presence of deteriorated hepatic cells. Hepatoprotective effects of silymarin were evidenced by the absence of cellular necrosis and inflammation in the liver section, particularly in rats treated with middle and high-dose silymarin.

Oxidative stress is a primary contributing factor in several pathological conditions, such as TP-induced liver injury, as it negatively affects cell membranes and function. Therefore, application of bioactive substances possessing antioxidantive properties may be effective therapeutic agents for preventing and treating hepatotoxicity (34). It has been reported that silymarin functions as an antioxidant by scavenging oxygen free radicals and decreasing lipid peroxidation to accelerate hepatocyte regeneration with minimal adverse actions (35-38). The results of the present study were consistent with previous studies (39-41). The activities of antioxidant enzymes, including SOD, CAT, GST and GSH-Px, were decreased, while MDA production increased in the liver of rats in the TP group.
When endogenous antioxidant systems were destroyed, an imbalance of oxidation and antioxidation occurred, which directly or indirectly damaged the intracellular proteins (42). Therefore, the mechanism of TP-induced liver injury may be associated with excessive levels of ROS and peroxides, which leads to induction of oxidative stress and lipid peroxidation (6). In the present study, pretreatment with silymarin, particularly high-dose silymarin, reversed the reduction in antioxidant enzymes activities to normal levels. These results indicate that silymarin may prevent TP from binding with hepatic lipids and proteins and thus inhibit lipid peroxidation and protect antioxidant enzymes. The capacity of silymarin for trapping free radicals has also been demonstrated in previous studies (37,43). Antioxidant action and anti-lipid peroxidation properties may be contributing factors in the protective effect of silymarin in TP-induced hepatocyte damage.

Inflammation is another important pathological mechanism that may be involved in TP-induced hepatotoxicity. In a previous report, TP activated hepatic Kupffer cell external antibody CD68 to release substantial amounts of TNF-α (44), which causes normal cells to release IL-6, IL-10 and IL-1β into the bloodstream, and is involved in the pathogenesis of viral hepatitis, alcoholic or nonalcoholic fatty liver, and ischemia-reperfusion injury (22,45,46). TNF-α is one of the transcription factors of the mitogen-activated protein kinase (MAPK) signaling pathway, which has been reported to mediate inflammation and apoptosis (47). When triggered by inflammatory cytokines such as TNF-α, MAPK cascades are initiated via p38 and JNK pathways to regulate activator protein-1, which subsequently leads to inflammatory responses and cell apoptosis (48). Phosphorylation of p38 and JNK may also be induced by oxidative stress, which stimulates the production of proinflammatory mediators and establishes a vicious cycle that aggravates hepatic injuries (49). Previous reports have indicated that silymarin, by acting on a variety of molecular targets, including cytokines and enzymes (50), restricts excessive inflammation caused by restraint stress (22) and alcohol (51). The results of the present study are consistent with these previous studies. Silymarin effectively inhibited the protein expression levels of TNF-α, p-p38 and p-JNK, which was increased significantly by TP injection, and subsequently led to significant reductions in the production of inflammatory cytokines (IL-6, IL-10 and IL-1β) and reduced inflammatory infiltration in middle or high-dose silymarin treatment groups compared with the TP group. These results indicate that a potential anti-inflammatory effect of silymarin may also contribute to its ability to attenuate TP-induced hepatotoxicity.

Rapid secretion of TNF-α may also lead to the activation of mitochondria-controlled apoptosis, the cascade reaction that begins with the release of Cyt C due to reduced mitochondrial membrane potential and destruction of the mitochondrial membrane (52), and results in the activation of caspase-3. ROS are thought to be responsible for damaging the mitochondrial membrane and releasing Cyt C (53). The release of Cyt C is also regulated by the Bcl-2-family of proteins that are situated on the mitochondrial membrane, of which Bcl-2 is the most typical antiapoptotic protein and Bax is the most typical proapoptotic protein (54). The ratio of Bcl-2/Bax determines whether a cell survives or undergoes cell death (54). When Bax expression is elevated by apoptosis-inducing factors, the reduced ratio leads to apoptosis. Additionally, JNK is also involved in mitochondrial intrinsic apoptotic pathways. JNK inhibits the expression of Bcl-2 and stimulates the expression of Bax. These key proteins cooperate to enhance the speed of apoptosis. Yang et al (55) previously demonstrated that TP-induced cell apoptosis is closely associated with the imbalance between Bcl-2 and Bax. Silymarin has been reported to maintain cell membrane fluidity and promote liver cell repair, which is thought to combat liver apoptosis (50). As expected, in the present study, TP-induced increases in the levels of Cyt C, Bax, JNK and c-caspase-3 were markedly prevented by silymarin treatment. Although the level of Bcl-2 did not change significantly between treatment groups, the alterations in the ratio of Bcl-2/Bax indicated the antia apoptotic effects of silymarin in a dose-dependent manner. These results were also verified by TUNEL staining observations. Qualitative and quantitative results of TUNEL staining demonstrated that the high-dose silymarin group had fewer TUNEL-positive cells and a lower apoptosis index compared with the TP group, which confirmed that inhibition of mitochondrial-controlled apoptosis may be the one of the protective mechanisms of silymarin against TP-induced hepatotoxicity.

Various studies have demonstrated that TP may be metabolized to three or four monohydroxylated metabolites, primarily by cytochrome P450 (CYP)3A4 and CYP3A2, respectively, in humans or rat liver microsomes during the phase I metabolic pathway (56-58). Therefore, hydroxylation and desaturation controlled by CYP3A were hypothesized to have important roles in TP detoxification (58). Further investigation of this potential mechanism is required in future studies.

In conclusion, the present study demonstrated that short-term oral administration of silymarin exerts pronounced effects in TP-induced liver injury. It was demonstrated to reduce lipid peroxidation and elevate antioxidant enzyme activity to enhance hepatic antioxidative defense systems, reduce excessive expression of proinflammatory cytokines, inhibit inflammatory signaling and ameliorate cell apoptosis to strengthen liver vitality. Silymarin exhibited satisfactory dose-dependent effects in preventing TP-induced hepatotoxicity and improving hepatic function. These results indicate that silymarin may be a potential candidate for treating TP-induced hepatotoxicity.

Acknowledgements

The present study was supported by grants from the Hong Kong, Macao and Taiwan Science and Technology Cooperation Program of China (grant no. 2014DFH30010), the Science and Technology Planning Project of Guangdong Province (grant nos. 2013B090800005, 2013B090600007 and 2013B090900026), Guangdong International Cooperation Project (grant no. 2013508102016) and the Science and Technology Major Project of Guangdong Province (grant no. 2012A080205001).

References

1. Jia L, Feihai S, Cuiwen G, Wenwen W, Xiaozhe S, Xinlu F, Min H, Jing J and Zhiying H: Activation of Nrf2 protects against triptolide-induced hepatotoxicity. PLoS One 9: 10, 2014.
23. Chen B: Triptolide: a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb *Tripterygium wilfordii* Hook F. Leuk Lymphoma 42: 253-265, 2001.

3. Liu B, Du C, Wu Y, Yang J, Huang J, Jiang Z and Zhang L: Caspase 3 is involved in the apoptosis induced by triptolide in HK-2 cells. Toxicol In Vitro 23: 598-602, 2009.

4. Phillips PA, Dudea V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle VE, Vickers SM and Saluja AK: Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70 (HSP70). Cancer Res 67: 9407-9416, 2007.

5. Mei ZN, Lia XK, Wu QR and Yang XL: The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle. Pharma Res 51: 345-351, 2005.

6. Fu Q, Huang X, Sha B, Xue M, Zhang P, Wang T, Liu L, Jiang Z and Zhang L: Inhibition of mitochondrial respiratory chain activity is involved in triptolide-induced liver injury. Fitoterapia 82: 1241-1248, 2011.

7. J Yang, X Liu, K Bhalla, C.N. Kim, A.M. Ibrado, J. Cai, T.I. Peng, D.F. Jones and X. Wang: Prevention of apoptosis by Bcl-2: Release of Cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.

8. Newmeyer DD: Hot papers-apoptosis-the release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. By R.M. Kluck, E. Bossy-Wetzel, D.R. Green, D.D. Newmeyer-Comments.Scientist 13: 160-167, 1999.

9. Shao LW, Lu L, Zhang YH, Yan S, Jin JD and Ken SY: Cordycepin induces apoptosis in human liver cancer HepG2 cells through extrinsic and intrinsic signaling pathways. Oncol Lett 12: 995-1000, 2016.

10. Abenavoli L, Capasso R, Milic N and Capasso F: Milk thistle in liver diseases: Past, present, future. Phytother Res 24: 1423-1432, 2010.

11. Pascual C, Gonz R, Armejo J and Muriel P: Effect of silymarin and silybin on oxygen radicals. Drug Devel Res 29: 73-77, 1993.

12. Crocenzzi FA and Roma MG: Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Curr Med Chem 13: 1055-1074, 2006.

13. Arafa HMM: Uroprotective effects of curcumin in cyclophosphamide-induced haemorrhagic cystitis paradigm. Basic Clin Pharmacol Toxicol 104: 393-399, 2009.

14. Avci H, Tunca R, Epikmen E, T. Birincioğlu SS, Seenk SB Murat M: Antioxidant and protective effect of Silymarin and Curcumin in experimental cyclophosphamide intoxication in rats. Kafkas Univ Vet Fak Derg 22: 693-701, 2006.

15. Schuppian D, Jia JD, Brinkhaus B and Hahn EG: Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology 30: 999-1004, 1999.

16. Hahn G, Lehmach HD, Kurten M, Uebel H and Vogel G: On the pharmacology and toxicology of silymarin, an antihepatotoxic active principle from *Silybum marianum* (L.) Gaertn. Arzneimittel-Forschung 34: 698-704, 1984.

17. Rajasekaran and Periyasamy M: Synthesis and evaluation of hepatoprotective activity of some new mannich bases bearing benztriazole moiety. J Chil Chem Soc 55: 366-370, 2010.

18. Jia R, Cao LP, Du JL, Xu P, Jeney G and Yin GJ: The protective effect of silymarin on the carbon tetrachloride (CCL4)-induced liver injury in common carp (*Cyprinus carpio*). In Vitro Cell Dev Biol-Anim 49: 155-161, 2013.

19. Pappachan JM, Antonio FA, Edavalath M and Mukherjee A: Milk thistle for the treatment of liver diseases: A therapeutic challenge for the new millennium. Hepatology 30: 1099-1104, 1999.

20. Ali MMH, Messia HS and Abdel-Latif HAT: Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats. Pharm Biol 54: 1198-1208, 2016.

21. Ali MMH, Jia K, He J, Shi C, Fang M, Song L, Zhang P, Zhao Y, Fu J and Li S: Establishment of the Tree Shrew as an alcohol-induced fatty liver model for the study of alcoholic liver diseases. PLoS One 10: 12, 2015.

22. Cao LJ, Li HD, Yan M, Li ZH, Gong H, Jiang P, Deng Y, Fang PF and Zhang BK: The protective effects of isoliquiritigenin and glycyrrhetinic acid against triptolide-induced oxidative stress in HepG2 cells involve Nrf2 activation. Evid Based Complement Alternat Med 2016: 8912184, 2016.

23. Saller R, Meier R and Brignoli R: The use of silymarin in the treatment of liver diseases: A review. Alternat Med 2016: 8912184, 2016.

24. Surai PF: Silymarin as a natural antioxidant: An overview of the current evidence and perspectives. Antioxidants (Basel) 4: 204-247, 2015.

25. Feng B, Meng R, Huang B, Shen SM, Bi Y and Zhu DL: Silymarin alleviates hepatic oxidative stress and protects against metabolic disorders in high-fat diet-fed mice. Free Radic Res 50: 314-326, 2016.

26. Zhang W, Hong RT and Tian TL: Silymarin's protective effects and possible mechanisms on alcoholic fatty liver for rats. Biomol Med 2: 264-299, 2013.

27. Gu HP, Gu XZ, Xu QT and Kang WY: Antioxidant activity in vitro and hepatoprotective effect of *Pholium maximowiczii* in vivo. Afr J Tradit Complement Altern Med 11: 46-52, 2014.

28. Simeonova R, Vitcheva V, Kondeva-Burdina M, Krasteva I, Manolov V and Mitchel M: Hepatoprotective and antioxidant effects of saponarin, isolated from *Gyspsophila trichotoma* Wend. on paracetamol-induced liver damage in rats. Biomed Res Int 2013: 757126, 2013.

29. Yuan L, Gu XZ, Yin ZH and Kang WY: Antioxidant activities in rats and hepato-protective effects of *Nelumbo nucifera* leaves in vivo. Afr J Tradit Complement Altern Med 11: 85-91, 2014.

30. Farrell GC: Drugs and steatohepatitis. Semin Liver Dis 22: 185-194, 2002.

31. Desplaces A, Choppin J, Vogel G and Trost W: The effects of silymarin on experimental phalloidine poisoning. Arzneimittel-Forschung 25: 89-96, 1975.

32. Woo K, Stewart SG, Kong GS, Finch-Edmondson ML, Dwyer BJ, Yeung SY, Abraham LJ, Kampmann SS, Diepeveen LA, Passman AM, et al: Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib. Eur J Med Chem 120: 275-283, 2016.

33. Imanishi H, Scales WE and Campbell DA: Tumor necrosis factor alpha alters the cytotoxic effect of hydrogen peroxide in cultured human hepatocytes. Biochem Biophys Res Commun 230: 120-124, 1997.

34. Auguste T, Vidal F, Lopez-Dupla M, Broch M, Gutierrez C, Olona M, Oltra C, Aguilar C, Gonzalez E, Quer JC, et al: A study on the TNF-alpha system in Caucasian Spanish patients with alcoholic liver disease. Drug Alcohol Depend 92: 91-99, 2008.

35. Kupfer RK and Choi EF: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405, 2010.
48. Herlaar E and Brown Z: p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 5: 439-447, 1999.
49. Jaeschke H: Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts. J Gastroenterol Hepatol 26: 173-179, 2011.
50. Jin YW, Zhao X, Zhang H, Li QS, Lu GD and Zhao XG: Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1 alpha-iNOS following rat lung ischemia-reperfusion injury. Exp Ther Med 12: 1135-1140, 2016.
51. Zholobenko A and Modriansky M: Silymarin and its constituents in cardiac preconditioning. Fitoterapia 97: 122-132, 2014.
52. Volbracht C, Leist M, Kolb SA and Nicotera P: Apoptosis in caspase-inhibited neurons. Mol Med 7: 36-48, 2001.
53. Wu D and Cederbaum AI: Oxidative stress and alcoholic liver disease. Semin Liver Dis 29: 141-154, 2009.
54. Kuwana T and Newmeyer DD: Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 15: 691-699, 2003.
55. Yang F, Zhuo L, Ananda S, Sun TY, Li SX and Liu L: Role of reactive oxygen species in triptolide-induced apoptosis of renal tubular cells and renal injury in rats. J Huazhong Univ Sci Technolog Med Sci 31: 335-341, 2011.
56. Tai T, Huang X, Su YW, Li J, Su Y, Jiang Z and Zhang L: Glycyrrhizin accelerates the metabolism of triptolide through induction of CYP3A in rats. J Ethnopharmacol 152: 358-363, 2014.
57. Han FM, Peng ZH, Wang JJ and Chen Y: In vivo effect of triptolide combined with glycyrrhetinic acid on rat cytochrome P450 enzymes. Yao Xue Xue Bao 48: 1136-1141, 2013.
58. Ye X, Li W, Yan Y, Mao C, Cai R, Xu H and Yang X: Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Toxicol Lett 192: 212-220, 2010.